Allspring中小型核心主动型ETF ASCE 深 沪
已收盘 11-13 16:00:00 美东时间
32.65
-0.080
-0.24%
华盛通- 最 高32.86
- 今 开32.86
- 成交量 10.26万股
- 最 低 32.278
- 昨 收 32.73
- 总市值 3.54亿
- 52周最高 36.3096
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 25.2319
- 委 比 0.00%
- 总股本 1085.70万
- 历史最高 36.3096
- 量 比 0.28
- 振 幅 1.78%
- 历史最低 24.0619
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma announced progress in its clinical trials, including completing dose escalation for CR-001 in the ASCEND trial and initiating the APOLLO trial for CR-002. The company achieved nine IND clearances with partner Kelun-Biotech and expects to dose over 2,000 patients by mid-2027. Financial results showed a cash position of $289.4 million, with plans to advance multiple combination therapies and expand clinical development.
11-12 21:15
Enerpac Tool Group Hosts 2026 Investor Day; Introduces Propel Strategy and Fiscal 2030 Targets
Enerpac Tool Group Corp. is hosting its 2026 Investor Day at the New York Stock Exchange, where leadership will discuss long-term growth strategies, including the PROPEL plan, and fiscal 2030 targets. CEO Paul Sternlieb highlighted the company's mission to expand technology leadership and deliver sustainable returns. A live webcast is available at ir.enerpactoolgroup.com, with presentation materials provided during the event. Enerpac, founded in ...
11-04 11:12
Amarin三季度实现盈利 得益于成本削减抵消营收下滑
Amarin公布2026年第三季度净利润为20万美元，运营成本的降低抵消了美国市场VASCEPA收入的下滑，同时国际市场需求实现增长。
10-29 00:01
Amarin (AMRN) 2026年第三季度业绩电话会：随着国际需求增长重返盈利
Amarin 2026年第三季度业绩电话会议：营收达3960万美元，录得两年来首次季度盈利，经营现金流为900万美元，且国际市场需求强劲。
10-28 21:51
Amarin (AMRN) Q3 2026 Earnings Call: Profitability Returns as International Demand Grows
Amarin Q3 2026 earnings call: $39.6 million revenue, first quarterly profit in two years, $9 million operating cash flow and strong international demand.
10-28 21:50
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
CAMP4 Therapeutics received EU approval to initiate a global Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, following clearances in the UK, Australia, and Argentina. The ASCEND trial aims to enroll patients globally, with first dosing expected in 4Q 2026. CMP-002 is designed to increase SYNGAP1 protein levels in patients with this rare genetic disorder, offering potential disease-modifying benefits.
10-27 12:00
ALLSPRING AMONG FIRST ASSET MANAGERS TO INTRODUCE ETF SHARE CLASSES
Three Fixed Income ETF Share Classes Start Trading Today CHARLOTTE, N.C., Oct. 21, 2026 /PRNewswire/ -- Allspring Global Investments™ (Allspring), a global asset management firm with more t...
10-21 20:30
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
ADMA Biologics announced the publication of a study detailing improvements in their IVIG manufacturing process, which effectively removes procoagulant impurities while maintaining immunoglobulin quality and increasing IgG yield. No thromboembolic events were reported for ADMA IVIG products during the postmarketing surveillance period. The optimized process enhances patient safety and product quality, supporting ADMA's commitment to advancing biop...
10-15 11:00
Conduent Investor Day Highlights ASCEND Long-Term Strategy
Conduent ( ($CNDT) ) has shared an announcement. On September 30, 2026, Conduen...
09-30 18:48
ASCE GYO Redirects TL 560 Million to Ankara Property Acquisitions
ASCE GAYRIMENKUL YATIRIM ORTAKLIGI A.S. ( ($TR:ASGYO) ) has provided an update....
09-30 00:15
